PURPOSE:: To evaluate the neovascular age-related macular degeneration (nAMD) course after endophthalmitis. METHODS:: Multicenter, retrospective series. RESULTS:: From 4/2013-10/2018, 196,598 intravitreal anti-VEGF injections were performed, with 75 cases of endophthalmitis (incidence 0.0381%). There was no association between intravitreal anti-VEGF drug (p=0.29), anesthetic method (p=0.26), povidone concentration (p=0.22), or any intra-procedure variable and endophthalmitis incidence. Seventy-two patients (96%) were treated with intravitreal tap & inject (vs 3 with pars plana vitrectomy). After endophthalmitis resolution, 17 patients (22.7%) were not re-treated for nAMD (inactive disease - 10 cases; follow-up 115±8.4 weeks). Patients required less frequent anti-VEGF injections post-infection (7.4±0.61 weeks vs 11.5±1.8 weeks; p=0.004). LogMAR visual acuity (VA) pre-infection was 0.585±0.053 (∼20/77). It worsened with endophthalmitis (1.67±0.08, ∼20/935; p<0.001) and again on POD1 (1.94±0.064, Count Fingers; p<0.001), but improved after re-initiating nAMD therapy (1.02±0.11, ∼20/209; p<0.001). Better VA on post-endophthalmitis week 1 (p=0.002) and reinitiation of nAMD treatment (p=0.008) were associated with better final VA, streptococcal culture with worse VA (p=0.028). The post-endophthalmitis treatment interval was associated with the anti-VEGF drug (aflibercept = ranibizumab > bevacizumab; p<0.001). CONCLUSIONS:: Patients with nAMD required fewer injections after endophthalmitis, suggesting a biological change in disease activity. nAMD became quiescent in 13.3% of eyes. Most achieved better outcomes with anti-VEGF reinitiation.